Comparison between Kawa-COVID-19 cohort and historical cohort in the Paris region
| Historical cohort (n=220) | Kawa-COVID-19 cohort (n=16) | P value | |
| Median age (IQR) | 2 (1.2 to 3.6) | 10 (4.7 to 12.5) | <0.0001 |
| Male gender | 128/220 (58%) | 8/16 (50%) | 0.63 |
| Clinical features: n (%) | |||
| Skin rash | 187/220 (85%) | 13/16 (81%) | 0.718 |
| Hands and feet erythema/oedema | 120/220 (54%) | 11/16 (68%) | 0.099 |
| Conjunctivitis | 176/220 (80%) | 15/16 (94%) | 0.342 |
| Dry cracked lips | 189/220 (85%) | 14/16 (87%) | 1 |
| Cervical lymphadenopathy | 114/220 (52%) | 6/16 (37%) | 0.309 |
| Complete Kawasaki disease: n (%) | 142/220 (64%) | 10/16 (62%) | 1 |
| Biological results: median (IQR) | |||
| CRP (mg/L) | 142 (95 to 197) | 207 (162 to 236) | 0.006 |
| Platelets (G/L) | 383 (289 to 491) | 188 (164 to 244) | <0.0001 |
| Lymphocytes (G/L) | 3.08 (1.86 to 4.77) | 1.15 (0.8 to 1.7) | <0.0001 |
| Natraemia (mmol/L) | 135 (134 to 137) | 130 (127 to 134) | 0.0003 |
| Albumin (g/L) | 25 (22 to 28) | 21 (19 to 23) | 0.024 |
| Echocardiography abnormalities: n (%) | 54/220 (26%) | 11/16 (69%) | 0.0004 |
| Myocarditis | 3/220 (1%) | 7/16 (44%) | 0.0001 |
| Coronary dilations | 42/220 (19%) | 3/16 (19%) | 1 |
| Pericarditis | 15/220 (7%) | 4/16 (25%) | 0.029 |
| Resistance to single IVIg | 45/220 (20%) | 10/16 (62%) | 0.004 |
| Origin: | 0.164 | ||
| Afro-Caribbean | 67/187 (36%) | 10/16 (62%) | 0.056 |
| Middle East | 44/187 (23%) | 2/16 (12%) | 0.532 |
| European | 48/187 (27%) | 4/16 (25%) | 1.0 |
| Asia | 28/187 (15%) | 0/16 | 0.136 |
CRP, C-reactive protein; IVIg, intravenous immunoglobulin.